MiMedx Group, Inc. (MDXG) Shares Bought by D.A. Davidson & CO.

D.A. Davidson & CO. increased its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 282.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,900 shares of the medical equipment provider’s stock after purchasing an additional 67,900 shares during the quarter. D.A. Davidson & CO. owned about 0.08% of MiMedx Group worth $641,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. UBS Asset Management Americas Inc. boosted its stake in MiMedx Group by 65.1% in the fourth quarter. UBS Asset Management Americas Inc. now owns 82,979 shares of the medical equipment provider’s stock valued at $1,046,000 after acquiring an additional 32,718 shares during the last quarter. PEAK6 Investments L.P. bought a new position in MiMedx Group in the fourth quarter valued at approximately $983,000. Dimensional Fund Advisors LP boosted its stake in MiMedx Group by 15.5% in the third quarter. Dimensional Fund Advisors LP now owns 48,930 shares of the medical equipment provider’s stock valued at $581,000 after acquiring an additional 6,573 shares during the last quarter. BlackRock Inc. boosted its stake in MiMedx Group by 1.1% in the fourth quarter. BlackRock Inc. now owns 13,607,325 shares of the medical equipment provider’s stock valued at $171,588,000 after acquiring an additional 147,214 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY boosted its stake in MiMedx Group by 2.4% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 419,100 shares of the medical equipment provider’s stock valued at $5,285,000 after acquiring an additional 10,000 shares during the last quarter. 79.28% of the stock is currently owned by institutional investors and hedge funds.

MDXG opened at $7.32 on Friday. The firm has a market capitalization of $777.24 million, a price-to-earnings ratio of 33.33, a PEG ratio of 0.91 and a beta of 1.54. MiMedx Group, Inc. has a twelve month low of $6.94 and a twelve month high of $7.05.

A number of brokerages have issued reports on MDXG. BidaskClub cut shares of MiMedx Group from a “hold” rating to a “sell” rating in a research note on Friday, May 4th. ValuEngine cut shares of MiMedx Group from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of MiMedx Group in a research note on Thursday, March 15th. Craig Hallum reaffirmed a “buy” rating on shares of MiMedx Group in a research note on Tuesday, February 27th. Finally, Lake Street Capital lowered shares of MiMedx Group from a “buy” rating to a “hold” rating and set a $9.00 target price on the stock. in a report on Friday, February 23rd. Four analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. MiMedx Group presently has an average rating of “Hold” and an average price target of $14.75.

About MiMedx Group

MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.

Institutional Ownership by Quarter for MiMedx Group (NASDAQ:MDXG)

Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply